June 28 Quick Takes: STARs aligning for BeiGene trifecta; plus venture money for Neurona, Vita, Lyndra, Currus and Eikonoklastes
Monday’s authorization to list on the Shanghai Stock Exchange’s STAR market sets BeiGene Ltd. (NASDAQ:BGNE; HKEX:6160) up to add its third listing, pending approval by China Securities Regulatory Commission. Hutchmed China Ltd. (NASDAQ:HCM; LSE:HCM) gained its third ticker last week when it debuted on the Stock Exchange of Hong Kong.
Neurona Therapeutics Inc.’s $41.5 million readies the San Francisco neural cell therapy company to start its Phase I/IIa study for chronic focal epilepsy this year for lead product NRTX-1001, which comprises interneurons that secrete the inhibitory neurotransmitter GABA. UCB Ventures and The Column Group co-led the round, with UCB’s Erica Whittaker joining Neurona’s board. The company, which did not disclose a round for the financing, has now raised a total of $135 million to date...